摘要
目的探讨血清低密度脂蛋白胆固醇对慢性肾病(CKD)患者病情进展的影响。方法选取2012年1月至2014年12月该院门诊规律随访1年以上,年龄18~70岁的1~2期CKD患者115例作为研究对象。根据CKD进展情况,通过筛选将所有患者分为非进展组60例和进展组40例。结果进展组患者女性比例大于非进展组,他汀类药物使用率、高密度脂蛋白胆固醇(LDL-C)达标率、终点估计肾小球滤过率(eGFR)低于非进展组,基线eGFR,终点总胆固醇(TC)、高密度脂蛋白胆固醇(HDL-C)、低密度脂蛋白胆固醇(LDL-C)高于非进展组,差异均有统计学意义(P〈0.05)。结论 LDL-C较基线升高(即水平大于1.075mmol/L)是CKD进展的独立危险因素。因此需要更加严格控制LDL-C达标标准,更加积极的采用药物治疗。
Objective To study the influence of serum low-density lipoprotein cholesterol level on the disease progression in the patients with chronic kidney disease. Methods 115 patients aged 18-70 years old with the stage 1- 2 chronic kidney disease (CKD) and regular outpatient follow up over 1 year from January 2012 to December 2014 were selected as the research subjects. According to the CKD progress,all patients were divided into the progression group(40 cases) and the non-progression group (60 cases). Results The female proportion in the progression group was more than that in the non-progression group, the use rate of statin drugs,reaching standard rate of high density lipoprotein cholesterol (LDL--C) and end point eGFR were lower than those in the non-progression group,baseline eGFR,end point total cholesterol (TC),high-density lipoprotein cholesterol (HDL-C) and LDL-C were higher than those in the non progression group,the differences were statistically significant (P〈0.05). Conclusion LDL-C in- crease from baseline(〉l. 075 mmol/L) is an independent risk factor for the progression of CKD. So it is needed to more strictly control LDL-C reaching standard criteria and more actively adopt the medication therapy.
出处
《检验医学与临床》
CAS
2015年第16期2418-2420,共3页
Laboratory Medicine and Clinic